Wechselwirkungen · Kaletra
Kaletra 100 mg/25 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 94
HOS-109096 · Präparat HOS-093083
Vardenafil Vardenafil: The use of vardenafil with Kaletra AUC: ↑ 49-fold is contraindicated (see section 4.3). Due to CYP3A inhibition by lopinavir/ritonavir. Ergot alkaloids Dihydroergotamine, Serum concentrations may be Concomitant administration of ergonovine, ergotamine, increased due to CYP3A Kaletra and ergot alkaloids are methylergonovine inhibition by lopinavir/ritonavir. contraindicated as it may lead to acute ergot toxicity, including vasospasm and ischaemia (see section 4.3). GI motility agent Cisapride Serum concentrations may be Concomitant administration of increased due to CYP3A Kaletra and cisapride is inhibition by lopinavir/ritonavir. contraindicated as it may increase the risk of serious arrhythmias from this agent (see section 4.3). HCV direct acting antivirals Elbasvir/grazoprevir Concomitant administration of (50/200 mg QD) Elbasvir: elbasvir/grazoprevir with Kaletra is AUC: ↑ 2.71-fold contraindicated (see section 4.3). Cmax: ↑ 1.87-fold C24: ↑ 3.58-fold
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): elbasvir (HOS-108814) methylergonovine (HOS-086155) cisapride (HOS-085610) ergot alkaloids (HOS-108807) lead (HOS-085592) grazoprevir (HOS-108815) ergotamine (HOS-086154) ergonovine (HOS-086153) dihydroergotamine (HOS-086152) vardenafil (HOS-086163)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-12-02T16:00:00Z · SHA-256 441d9e5f9e4b42d645e4bd802abc892cef6574b0be5b3f18d2a96678774ae365 · Passage 91eb7faa6d9a78f7331b7a384e745b4c17e75fcbe434c0f326e2d031b1ee9d48 · Zeichen 49888–51668 im Abschnitt